Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, Zacks reports.
Alpha Tau Medical Stock Performance
NASDAQ DRTS opened at $3.10 on Tuesday. Alpha Tau Medical has a one year low of $1.75 and a one year high of $4.39. The stock has a 50-day moving average of $2.64 and a 200 day moving average of $2.90. The company has a market capitalization of $218.18 million, a price-to-earnings ratio of -7.21 and a beta of 0.92.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
- Five stocks we like better than Alpha Tau Medical
- Stock Market Sectors: What Are They and How Many Are There?
- Here’s The Bull Case For Roku Stock With Double-Digit Upside
- Why Invest in 5G? How to Invest in 5G Stocks
- Spotify Stock’s Rally Still Has Legs To Run Higher
- What Does Downgrade Mean in Investing?
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
